DUBLIN--(BUSINESS WIRE)--The "Global Myocardial Infarction (MI) Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The myocardial infarction (MI) therapeutics market will register a CAGR of almost 3% by 2023.
MI along with other cardiovascular problems, is the leading cause of premature deaths in the world. The rising incidence of coronary artery disease, obesity, diabetes, and hypertension, along with a sedentary lifestyle, smoking, and reduced physical activities, is expected to increase the risk factors for cardiovascular diseases including MI.
Apart from these factors, the rapid rise in the geriatric population is increasing the incidence of MI. Hence, the incidence of MI is expected to increase with the rapidly expanding geriatric population. The rising incidence of MI will propel the growth of the market during the forecast period.
Increased adoption of novel antithrombotics
Novel antithrombotics such as NOACs and antiplatelet drugs (BRILINTA and Effient) possess the potential to expand the scope of the treatment for MI. These drugs offer significant advantages such as target specificity. The market also contains specific antidotes for these drugs, which can help prevent life-threatening or uncontrolled bleeding.
Extensive use of generics
A generic drug is a medication that is the same as the existing approved branded drug in terms of dosage form, safety, strength, route of administration, quality, and performance characteristics. Generic drugs are allowed for sale after the expiry of the patent of the original branded drug. Thus, generic drugs have comparatively lower prices than the branded drugs.
Competitive Landscape
The market appears to be moderately concentrated and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
Key Players
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Pfizer Inc.
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
PART 07: MARKET SEGMENTATION BY PRODUCT
- Comparison by product
- Antithrombotics - Market size and forecast 2018-2023
- Vasodilators - Market size and forecast 2018-2023
- Thrombolytics - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
- MI type
PART 10: GEOGRAPHIC LANDSCAPE
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
- Stem cell therapies for MI
- Advanced diagnostic modalities for MI
- Rising number of patient-support initiatives
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Pfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/research/6jggb3/global_myocardial?w=4
